Skip to content
10-Q

Quarterly Report

Structure Therapeutics Inc. GPCR

0001104659-26-057230

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 213.22M sh
Shares Diluted Q1 2026 · Mar 31, 2026 217.33M sh
Shares Diluted Q1 2026 · Mar 31, 2025 172.05M sh
Capex Q1 2026 · Mar 31, 2026 $1.18M
Capex Q1 2026 · Mar 31, 2025 $314K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $15.23M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$52.23M
Short Term Investments Q1 2026 · Mar 31, 2026 $1.14B
Short Term Investments Q1 2026 · Dec 31, 2025 $646.57M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $316.17M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $799.62M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.45B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.52B
Stockholders Equity Q1 2026 · Mar 31, 2025 $824.64M
Stockholders Equity Q1 2026 · Dec 31, 2024 $864.84M
Current Liabilities Q1 2026 · Mar 31, 2026 $56.98M
Current Liabilities Q1 2026 · Dec 31, 2025 $63.29M
Total Liabilities Q1 2026 · Mar 31, 2026 $61.03M
Total Liabilities Q1 2026 · Dec 31, 2025 $67.54M
Current Assets Q1 2026 · Mar 31, 2026 $1.49B
Current Assets Q1 2026 · Dec 31, 2025 $1.57B
Total Assets Q1 2026 · Mar 31, 2026 $1.51B
Total Assets Q1 2026 · Dec 31, 2025 $1.58B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.35
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.27
Eps Basic Q1 2026 · Mar 31, 2026 −$0.35
Eps Basic Q1 2026 · Mar 31, 2025 −$0.27
Sga Expense Q1 2026 · Mar 31, 2026 $22.87M
Sga Expense Q1 2026 · Mar 31, 2025 $13.44M
Rd Expense Q1 2026 · Mar 31, 2026 $66.51M
Rd Expense Q1 2026 · Mar 31, 2025 $42.87M
Net Income Q1 2026 · Mar 31, 2026 −$75.97M
Net Income Q1 2026 · Mar 31, 2025 −$46.83M
Operating Income Q1 2026 · Mar 31, 2026 −$89.38M
Operating Income Q1 2026 · Mar 31, 2025 −$56.31M